Condition · Evidence Review
Fact-checked by Dr. Adam Kennah, MD on . See our fact-checking policy.
In March 2024 the FDA approved semaglutide 2.4 mg (Wegovy) for reducing the risk of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease — the first weight-management drug ever approved for a cardiovascular outcome indication. The basis was the SELECT trial, which showed a 20% reduction in MACE over a median 39.8 months of follow-up.
SELECT enrolled 17,604 adults aged 45+ with BMI ≥27 kg/m² and established cardiovascular disease but without diabetes. Participants were randomized to semaglutide 2.4 mg once weekly or placebo, on top of guideline-directed cardiovascular medical therapy. The primary endpoint was the composite of cardiovascular death, non-fatal MI, or non-fatal stroke.
After a median follow-up of 39.8 months, the primary endpoint occurred in 6.5% of semaglutide patients vs 8.0% of placebo — a 20% relative risk reduction. The benefit emerged within the first six months and persisted throughout follow-up.
STEP-HFpEF (2023) and STEP-HFpEF DM (2024) showed that semaglutide 2.4 mg improved symptoms (Kansas City Cardiomyopathy Questionnaire score), exercise capacity (6-minute walk distance), and weight in patients with heart failure with preserved ejection fraction and obesity — both with and without diabetes. This is a distinct indication from the SELECT MACE benefit.
Probably not entirely. The MACE curves separate within months — faster than would be expected from weight loss alone. Mechanistic candidates include reduced systemic inflammation (CRP drops 30–40%), improved endothelial function, modest blood pressure reduction (~3 mmHg systolic), and improved lipid profiles. The current consensus is that semaglutide CV benefit is multifactorial.
Per the FDA label, semaglutide 2.4 mg is indicated to reduce CV risk in adults with overweight or obesity (BMI ≥27) and established cardiovascular disease. "Established CV disease" means prior MI, prior ischemic stroke, or symptomatic PAD. Primary prevention is not currently an FDA indication.
SURPASS-CVOT, the dedicated cardiovascular outcome trial for tirzepatide in T2D, is expected to read out in 2026. SURMOUNT-MMO, the cardiovascular outcome trial in obesity without diabetes, is enrolling. Until those results, tirzepatide's CV benefit profile is inferred from biomarkers (LDL, BP, weight, A1c) rather than hard outcomes.
For a patient with BMI ≥27, established CV disease, and adequate insurance, semaglutide 2.4 mg is now a guideline-supported addition to standard CV medical therapy. For patients without insurance coverage of Wegovy, compounded semaglutide delivers the same molecule — but it does not carry the FDA CV indication and is off-label for that use.
SELECT (Lincoff et al., NEJM 2023), STEP-HFpEF (Kosiborod et al., NEJM 2023), STEP-HFpEF DM (Kosiborod et al., NEJM 2024). See our research bibliography for full citations.